American College of Clinical Pharmacy
      Search      Cart
         

Reinventing Yourself: “Old” Drugs with “New” Uses

Monday, October 28, 2019 from 9:00 AM to 10:30 AM EST at 2nd Floor: Murray Hill

Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-19-163-L01-P
Activity Type: An Application-Based Activity

This session will focus on the repositioning of old drugs for new uses that are either positive, such as discoveries of new therapeutic indications, or negative such as discoveries of new abuse liability. Gabapentin has been marketed in the U.S. for nearly 25 years, though new evidence indicates that it may be subject to abuse, which has warranted re-evaluation of its nonscheduled status. Medical marijuana continues to gain traction in many states as new evidence emerges that expands its clinical utility. Ketamine, used primarily in anesthesia, is becoming increasingly popular as a robust treatment option for those with treatment-resistant major depressive disorder and post-traumatic stress disorder. The goal of this session is to analyze the evidence driving these emerging trends and to educate attendees on potential practice implications.

Speakers
  • Alyssa M. Peckham, Pharm.D., BCPPModerator: Alyssa M. Peckham, Pharm.D., BCPP
    Assistant Professor and Clinical Addiction Specialist, Northeastern University, Bouvé College of Health Sciences, School of Pharmacy, Boston, Massachusetts
      View Biography

Gabapentin Abuse: A “Neu Pain” for Clinicians
9:00 AM

Speakers
  • Kirk E. Evoy, Pharm.D., BCACP, BC-ADM, CTTSSpeaker: Kirk E. Evoy, Pharm.D., BCACP, BC-ADM, CTTS
    Clinical Assistant Professor, College of Pharmacy, The University of Texas at Austin; Adjunct Assistant Professor, School of Medicine, The University of Texas Health San Antonio; Ambulatory Care Pharmacist, Southeast Clinic, University Health System
      View Biography


Learning Objectives
1. Identify abuse potential of gabapentin and trends in the prevalence of gabapentin abuse, both globally and nationally, and with or without opioids.
2. Compare and contrast medical harm and healthcare utilization rates resulting from gabapentin-only abuse versus gabapentin abuse with concomitant opioids.
3. Distinguish patients with the highest risk of future gabapentin abuse based on comorbid conditions and concomitant medications.
4. Evaluate state-level and national legislative efforts assisting healthcare personnel in identifying and mitigating gabapentin abuse.
New Indications for Medical Marijuana: Weeding Through the Evidence
9:30 AM

Speakers
  • Ann M. Philbrick, Pharm.D., FCCP, BCPS, BCACPSpeaker: Ann M. Philbrick, Pharm.D., FCCP, BCPS, BCACP
    Associate Professor, University of Minnesota College of Pharmacy, Minneapolis, Minnesota; Bethesda Family Medicine Clinic, Saint Paul, Minnesota
      View Biography


Learning Objectives
1. Discuss the pharmacology of medical marijuana and proposed therapeutic mechanism of action.
2. Identify potential medical conditions for which medical marijuana may be useful.
3. Recognize potential adverse effects of medical marijuana and develop appropriate patient counseling points.
Ketamine for MDD and PTSD: Analyzing the “Psych” in Psychedelic
10:00 AM

Speakers

Learning Objectives
1. Discuss the potential role of ketamine in the treatment of PTSD and MDD.
2. Review the current scientific evidence of ketamine therapy for treatment of PTSD and MDD.
3. Evaluate the common clinical barriers to treatment with ketamine infusions.